EcoDrugPlus

Cell Division Cycle 7

Ensembl ID : ENSDCDG00000019849
Gene Symbol: CDC7
3 Cross references
209 Possible Orthologues:

Cellular Tumor Antigen P53-Like

Ensembl ID : ENSDCDG00000022652
Gene Symbol: LOC114787665
2 Cross references
231 Possible Orthologues:

Checkpoint Kinase 1

Ensembl ID : ENSDCDG00000005581
Gene Symbol: CHEK1
3 Cross references
179 Possible Orthologues:

Checkpoint Kinase 2

Ensembl ID : ENSDCDG00000020862
Gene Symbol: CHEK2
3 Cross references
206 Possible Orthologues:

Chemokine (C-X-C Motif) Receptor 4a

Ensembl ID : ENSDCDG00000023342
Gene Symbol: CXCR4A
1 Cross references
201 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSDCDG00000004766
Gene Symbol: CCKAR
3 Cross references
201 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSDCDG00000018539
Gene Symbol: LOC114797305
2 Cross references
195 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSDCDG00000003940
Gene Symbol: LOC114791226
3 Cross references
198 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSDCDG00000016939
Gene Symbol: LOC114803037
3 Cross references
259 Possible Orthologues:

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSDCDG00000026336
Gene Symbol: CETP
3 Cross references
151 Possible Orthologues:

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSDCDG00000026629
Gene Symbol: CHRM1
3 Cross references
104 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSDCDG00000008702
Gene Symbol: CHRM2
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).